Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) approved an expanded label for CASGEVY (exagamglogene autotemcel) for patients aged 2 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). This approval makes CASGEVY the first and only approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. Approximately 5,500 additional children in the U.S. are now eligible for this one-time therapy, which was previously approved for people 12 years and older.

The approval decision was granted 53 days after filing and was the eighth approval selected for the Commissioner’s National Priority Voucher (CNPV) pilot program. Vertex has established a network of independently operated, authorized treatment centers (ATCs) throughout the U.S., with more than 75 activated ATCs currently available to offer CASGEVY to eligible patients.

Clinical Trial Data and Mechanism

CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy consisting of the patient’s own hematopoietic stem and progenitor cells, administered as a one-time single dose for intravenous infusion. The cells are edited at the erythroid specific enhancer region of the BCL11A gene, resulting in the production of high levels of fetal hemoglobin (HbF). In patients with severe SCD, this prevents red blood cells from forming abnormal sickle shapes. In patients with TDT, it increases HbF and total hemoglobin levels, eliminating dependence on regular red blood cell transfusions.

The safety and effectiveness in patients aged 5 years to less than 12 years with SCD were evaluated in a clinical trial of 11 patients. All eight evaluable patients achieved the primary efficacy outcome of VF12, defined as no protocol-defined severe VOCs for at least 12 consecutive months within the first 24 months after infusion. For TDT, a trial of 15 patients aged 5 to less than 12 years showed that eight of nine evaluable patients achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months. Extrapolation to the younger pediatric age population was granted to expand the indication to 2 years of age and above for both conditions.

Adverse Reactions and Regulatory Status

The most common Grade 3 or 4 non-laboratory adverse reactions were mucositis and febrile neutropenia in patients with SCD and TDT, and decreased appetite in patients with SCD. Warnings include neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions, and off-target genome editing risk. Full myeloablative conditioning is administered prior to treatment with CASGEVY. Regulatory review for label expansion is currently underway in the Kingdom of Saudi Arabia and the United Kingdom.

In June, the FDA accepted Vertex’s Biologics License Application submission for povetacicept in adults with immunoglobulin A nephropathy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise.

Vertex Pharmaceuticals has delivered significant shareholder value over the past half-decade, outperforming the market by 8.53% on an annualized basis. The company generated an average annual return of 19.73% during this period, highlighting the impact of compounded returns on long-term investment growth. Currently, Vertex Pharmaceuticals holds a market capitalization of $125.63 billion.

Investment Growth Analysis

The performance of Vertex Pharmaceuticals stock over the last five years illustrates the potential for wealth creation through consistent market outperformance. Investors who allocated capital to the stock five years ago have seen substantial appreciation in their holdings.

Hypothetical Investment Returns

The following table details the growth of a hypothetical investment in Vertex Pharmaceuticals over the specified period:

The key insight from this data is the significant difference compounded returns can make to cash growth over an extended period. With a current share price of $494.99, the stock has multiplied the value of initial investments made five years ago.